Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer
Primary objective:

To assess response rate. To record the clinical improvement in relation to stage and histopathological grading.

Secondary objective:

To determine progression free survival. To find out overall survival. To evaluate the safety of the study regimen.
Ovarian Neoplasms
DRUG: Docetaxel|DRUG: Carboplatin
Measurements of the disease (assessed clinically and/or by CA-125), At baseline and from administration of drug to end of treatment|Response rate, From start to end of treatment|Clinical examination including neurologic examination, vital signs (blood pressure, heart rate, temperature), weight, assessment of any residual toxicity due to previous therapy, assessment of performance status., From the beginning to the end of study|Adverse events, From the beginning to the end of the study
Progression free survival, From administration of drug up to end of study|Overall survival, From administration of drug to end of study|Biology and Hematology laboratory determinations, From the beginning to the end of the study
Primary objective:

To assess response rate. To record the clinical improvement in relation to stage and histopathological grading.

Secondary objective:

To determine progression free survival. To find out overall survival. To evaluate the safety of the study regimen.